Understanding the Urgency of Early Lung Cancer Detection in Brazil
Lung cancer remains one of the leading causes of cancer-related deaths in Brazil, often diagnosed at advanced stages when treatment options are limited. The Brazilian public health system, known as SUS or Sistema Único de Saúde, serves millions and faces unique challenges in delivering timely screenings to high-risk populations, particularly smokers and former smokers in underserved regions.
Recent research initiatives are addressing this gap by exploring low-dose computed tomography (LDCT) as a viable screening tool within the SUS framework. These efforts build on earlier trials and aim to create evidence-based guidelines that could transform outcomes for countless Brazilians.
The Landmark BRELT Trials Paving the Way
The First Brazilian Lung Cancer Screening Trial, or BRELT1, conducted between 2013 and 2016, screened 790 high-risk volunteers using LDCT. Results showed a 1.5% prevalence of lung cancer, comparable to international studies, with biopsy rates around 3% despite Brazil's high tuberculosis prevalence. This demonstrated that LDCT screening is feasible even in regions with endemic granulomatous diseases.
Building on this, BRELT2 expanded the scope, involving over 3,800 participants across multiple states and confirming a 2% cancer detection rate with similar low biopsy needs. These trials highlighted the potential for real-world implementation in both public and private sectors, setting the stage for broader SUS integration.
INCA's Groundbreaking 2026 Study: A New Chapter for SUS
In April 2026, the National Cancer Institute (INCA) launched a pioneering two-year study to evaluate the feasibility of a national lung cancer screening program within the SUS. Partnering with Rio de Janeiro's municipal health secretariat and funded by AstraZeneca, the initiative targets at least 397 participants through collaboration with smoking cessation programs serving around 50,000 individuals.
The study seeks to generate robust scientific data to support a national guideline, focusing on early detection to reduce mortality rates. With 85% of lung cancer cases linked to tobacco use, this research prioritizes high-risk groups and aims to overcome logistical and economic barriers in public healthcare delivery.
How LDCT Screening Works Step by Step
Low-dose CT scans use minimal radiation to create detailed lung images, detecting small nodules that might indicate early-stage cancer. Participants first undergo eligibility assessment based on age, smoking history (typically 20-30 pack-years), and quit timelines. Scans are then performed annually or as needed, followed by multidisciplinary review for suspicious findings.
Positive results lead to further diagnostics like biopsies or PET scans, ensuring accurate staging. This process emphasizes shared decision-making between patients and physicians to balance benefits against risks such as false positives or overdiagnosis.
Photo by Angiola Harry on Unsplash
Key Benefits and Real-World Impact
Early detection through screening can shift diagnoses from late-stage (where survival is low) to stage I, where five-year survival exceeds 80%. Brazilian studies show reduced overdiagnosis concerns, with follow-up data from BRELT1 indicating strong potential for curative treatments.
Economically, cost-effectiveness analyses confirm LDCT screening delivers value in high-risk SUS populations, potentially lowering long-term treatment costs by catching cancers early. This aligns with global evidence from trials like the National Lung Screening Trial, adapted to Brazil's unique context.
Challenges in Implementing Screening Across SUS
Despite promise, barriers include limited access to LDCT machines in rural areas, workforce training needs, and integration with existing smoking cessation services. Economic constraints also play a role, as targeted therapies remain expensive even when diagnosed early.
Regional disparities in healthcare infrastructure further complicate rollout, requiring targeted investments in equipment and education for primary care providers.
Stakeholder Perspectives and Expert Insights
Researchers from INCA emphasize the study's role in building national policy. Clinicians highlight reduced mortality potential, while patients in pilot programs report increased awareness and proactive health management. Public health advocates stress equity, ensuring screenings reach low-income and indigenous communities.
International collaborations, such as with AstraZeneca, bring expertise in scaling programs successfully.
Future Outlook and Actionable Steps
If successful, the INCA study could lead to a nationwide LDCT program by 2028, integrating with SUS digital health records for better follow-up. Continued research on liquid biopsies and AI-assisted imaging may further enhance accuracy and accessibility.
Brazilians at risk are encouraged to discuss screening with primary care physicians, participate in cessation programs, and advocate for expanded services through local health councils.
Photo by National Cancer Institute on Unsplash
Supporting Resources for Readers
For more details on lung health and screening guidelines, explore trusted sources like the Brazilian Ministry of Health and INCA websites. Community health workers play a vital role in educating populations about early signs such as persistent cough or shortness of breath.